Study to Assess PDM608 in Healthy Adult Subjects

A Two-Part Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of PDM608 in Healthy Adult Subjects

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.

This is a 2-part, single-center, first-in-human study of single ascending doses (SAD; Part 1) and multiple ascending doses (MAD; Part 2) of PDM608 in healthy adult subjects.

Part 1 is a double-blind, randomized, placebo-controlled assessment of subcutaneous (SC) SAD administrations of PDM608 across 5 cohorts of subjects. All SAD cohorts will follow a sentinel design. Following completion of each cohort, safety and tolerability data through 96 hours post-dose will be reviewed to determine whether to progress to the next dose level and the dose level for the next cohort.

Part 2 is a double-blind, randomized, placebo-controlled assessment of SC MAD administrations (once weekly for 4 weeks) of PDM608 across up to 4 cohorts of subjects. Following completion of each cohort the safety and tolerability data 96 hours post last dose will be reviewed to determine whether to progress to the next dose level and the dose level to be administered.

Inclusion Criteria:

• Healthy men, or women of non-childbearing potential
• Must agree to use an adequate method of contraception
• Body mass index (BMI) of 18.0 to 33.0 kg/m2 as measured at screening

Exclusion Criteria:

• Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
• Significant allergy requiring treatment
• History of clinically significant autoimmune, cardiovascular, renal, hepatic, chronic respiratory or GI disease (except cholecystectomy), neurological or psychiatric disorder, illness/infection/hospitalization or surgical procedure within 30 days prior to first dose of study drug or any uncontrolled medical illness as judged by the investigator
• Have poor venous access that limits phlebotomy
• Evidence of current SARS-CoV-2 infection or exposure to confirmed infection within 10 days prior to the first dose of study drug
• Clinically significant abnormal clinical chemistry, hematology or urinalysis
• Hepatitis B, Hepatitis C, HIV, TB
• Renal impairment
• Pregnant or lactating women or men with pregnant or lactating partners
• Received any IMP in a clinical research study within 5 half-lives or within 30 days prior to first dose (whichever is longer)
• Taking any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g per day acetaminophen and HRT) in the 14 days or 5 half-lives (whichever is longer) before IMP administration
• COVID-19 vaccine within 14 days prior to first dose or have a COVID-19 vaccine scheduled between their first dose of IMP and last dose of IMP.
• Drug or alcohol abuse in the past 2 years
• Regular alcohol consumption in men >21 units per week and women >14 units per week (1 unit = 12 oz 1 bottle/can of beer, 1 oz 40% spirit or 5 oz glass of wine)
• Positive alcohol urine test at screening or first admission
• Current and within the last six months-smokers, e-cigarettes and nicotine replacement users
• Donation of blood within 2 months or donation of plasma within 7 days prior to first dose of study medication
• Subjects who are, or are immediate family members of, a study site or Sponsor employee